European heart journal open最新文献

{"title":"Efficacy and safety of renal denervation therapy in hypertension: a meta-analysis.","authors":"Husam M Salah, Jorge Antonio Gutierrez, Jennifer A Rymer, Hidenori Yaku, Rajesh V Swaminathan, Manesh R Patel, Marat Fudim","doi":"10.1093/ehjopen/oeaf026","DOIUrl":"10.1093/ehjopen/oeaf026","url":null,"abstract":"","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 2","pages":"oeaf026"},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationale and design of the acetazolamide as a chloride sparing diuretic in patients admitted with heart failure (ADA-HF) trial.","authors":"Joseph J Cuthbert, Elton Luo, Aia S M Ahmed, Meenakshy Ajith, Hafiz Butt, Henrietta Pinhol, Felix Baffour Korsah, Jeanne Bulemfu, Sarah Ford, Grant Constable, Leanne Cox, Alan S Rigby, Andrew L Clark","doi":"10.1093/ehjopen/oeaf019","DOIUrl":"10.1093/ehjopen/oeaf019","url":null,"abstract":"<p><strong>Aims: </strong>The Acetazolamide as a chloride-sparing Diuretic in patients Admitted with Heart Failure (ADA-HF) trial will assess the safety and diuretic effect of oral ACZ given alongside a high-dose IV loop diuretic in patients admitted to the hospital with heart failure (HF) and severe fluid retention. Hypochloraemia is common in patients with HF and is associated with worse outcomes, but there are few treatment options available: we will also assess whether ACZ reduces urine chloride loss.</p><p><strong>Methods and results: </strong>The ADA-HF trial is a single centre, open-label, randomized-controlled trial of ACZ 250 mg twice daily plus standard care vs. standard care alone. The trial duration is 4 days. We will recruit 50 patients with severe peripheral oedema due to HF requiring standard care (240 mg of IV furosemide per day given via continuous infusion at 10 mg per hour). The co-primary endpoints are (1) the difference in net fluid loss daily, and over 4 days; and (2) difference in serum chloride concentrations between baseline and day 4. The trial has 80% power to detect a difference in fluid balance of 500-1000 mL per day; and a difference in serum chloride concentration of 1 mmol/L per day. Secondary endpoints include but are not limited to: time to recruit per patient; rate of adverse events; rate of recruitment; and cause-specific rate of drop-out of the study.</p><p><strong>Conclusion: </strong>ACZ may be a useful adjunct to diuretic therapy, but the safety and diuretic efficacy of oral ACZ when used alongside high-dose loop diuretics is unknown. ADA-HF will complement the ADVOR trial and may clarify what role ACZ may have for patients with severe congestion.</p><p><strong>Trial registration: </strong>ISRCTN registry. ISRCTN13060336. Registered on 09/02/2023. URL: https://doi.org/10.1186/ISRCTN13060336.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 2","pages":"oeaf019"},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causes and clinical impact of initial misdiagnosis of acute type A aortic dissection.","authors":"Karl Teurneau-Hermansson, David von Rosen, Jacob Ede, Mårten Larsson, Johan Sjögren, Per Wierup, Shahab Nozohoor, Igor Zindovic","doi":"10.1093/ehjopen/oeaf027","DOIUrl":"10.1093/ehjopen/oeaf027","url":null,"abstract":"<p><strong>Aims: </strong>The high mortality in untreated acute type A aortic dissection (ATAAD) stresses the need for prompt diagnosis and immediate surgical treatment. Our aim was to evaluate the frequency and clinical impact of misdiagnosis and delayed diagnosis of ATAAD.</p><p><strong>Methods and results: </strong>This was a single-centre, retrospective, observational study including all ATAAD patients with available admission charts between 2001 and 2021 in an area of 1.9 million inhabitants in southern Sweden. The primary endpoints were initial misdiagnosis, delayed diagnosis, and 30-day mortality. Surgical treatment was a secondary endpoint. Independent predictors of misdiagnosis and 30-day mortality were identified by multivariable logistic regression and subgroup analyses by severity of clinical presentation were performed. There were 556 patients included in the study (418 surgically treated and 138 non-surgically treated), and 45.3% were initially misdiagnosed. Misdiagnosed patients were more often female (47.6 vs. 35.9%; <i>P</i> = 0.005) and demonstrated significantly lower rates of syncope, hypotensive shock, and malperfusion. Patients without signs of malperfusion subjected to diagnostic delay were less likely offered surgical treatment (74.0 vs. 91.5%; <i>P</i> < 0.001) and had higher 30-day mortality (21.3 vs. 10.8%; <i>P</i> = 0.040). Female sex was an independent predictor of misdiagnosis (OR: 1.748; 95% CI 1.145-2.668; <i>P</i> = 0.010), but neither misdiagnosis nor delayed diagnosis were independent predictors of 30-day mortality.</p><p><strong>Conclusion: </strong>Although misdiagnosis and delayed diagnosis did not influence overall 30-day mortality, delayed diagnosis led to significantly higher 30-day mortality in the large group of patients presenting without signs of malperfusion, likely caused by the observed higher risk of being denied surgical treatment.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 2","pages":"oeaf027"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive behavioural therapy targeting cardiac anxiety post-myocardial infarction: results from two sequential pilot studies.","authors":"Amanda Johnsson, Brjánn Ljótsson, Björn E Liliequist, Helga Skúladóttir, Linnea Maurex, Ida Boberg, Eva Ólafsdóttir, Sofia Klavebäck, Frieder Braunschweig, Linda G Mellbin, Josefin Särnholm","doi":"10.1093/ehjopen/oeaf020","DOIUrl":"10.1093/ehjopen/oeaf020","url":null,"abstract":"<p><strong>Aims: </strong>Cardiac anxiety, which is cardiac-related fear and avoidance behaviours, is common following myocardial infarction (MI) and has been associated with increased risk for cardiovascular events. However, there are currently no treatments specifically designed to target cardiac anxiety. The aim of the two pilot studies was to evaluate an exposure-based cognitive behavioural therapy protocol (MI-CBT) targeting cardiac anxiety following MI, assessing feasibility, acceptability, and the intervention's potential for reducing cardiac anxiety and improving health-related quality of life (QoL).</p><p><strong>Methods and results: </strong>A series of two sequential, uncontrolled pilot studies were conducted. In Pilot Study 1 (<i>n</i> = 15), MI-CBT was delivered via face-to-face videoconference, while Pilot Study 2 (<i>n</i> = 23) was delivered online. Patients with a history of MI (≥6 months before assessment, type 1 ST- or non-ST-segment elevation MI, and elevated cardiac anxiety as per clinical interview) were included. The interventions lasted 8 weeks and were therapist-led, with key components including exposure to cardiac-related symptoms and reduction of avoidance behaviours. Participants completed self-rated assessments, including the Cardiac Anxiety Questionnaire (CAQ) and the 12-Item Short Form Health Survey (SF-12), at baseline, post-treatment, and 6-month follow-up. Treatment adherence and satisfaction were high. Cognitive behavioural therapy led to a large reduction in cardiac anxiety, as measured by the CAQ (<i>P</i> < 0.001), and significant improvements in health-related QoL, as measured by the SF-12 (<i>P</i> < 0.001), in both pilot studies.</p><p><strong>Conclusion: </strong>These studies suggest that exposure-based CBT is a feasible, acceptable, and promising approach to reduce cardiac anxiety and improve QoL following MI. A randomized controlled trial should be conducted to evaluate the efficacy of the intervention.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 2","pages":"oeaf020"},"PeriodicalIF":0.0,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline characteristics and 1-year outcome by left ventricular function in the CABG PREFERS.","authors":"Ulrika Löfström, Cecilia Linde, Maria J Eriksson, Eva Maret, Matthias Corbascio, Mattias Ekström, Patrik Lyngå, Håkan Wallén, Bengt Persson, Hans Persson, Camilla Hage","doi":"10.1093/ehjopen/oeaf014","DOIUrl":"10.1093/ehjopen/oeaf014","url":null,"abstract":"<p><strong>Aims: </strong>The aim of this study is to describe patients undergoing elective coronary artery bypass grafting (CABG) surgery by left ventricular (LV) function at baseline and 1-year follow-up.</p><p><strong>Methods and results: </strong>In the single-centre CABG PREFERS cohort prospective study, we classified patients planned for elective CABG by LV function assessed by echocardiography and N-terminal pro-B-type natriuretic peptide (NT-proBNP) into three phenotype groups: preserved ejection fraction (EF; pEF), reduced EF (rEF), and normal, irrespective of signs or symptoms of heart failure (HF). At baseline and 1-year follow-up, electrocardiogram, echocardiography, cardiac magnetic resonance imaging, laboratory tests, and quality of life were assessed. Sixty-one of a total of 136 patients (45%) had systolic and/or diastolic LV dysfunction (25% pEF, 20% rEF, and the rest 55% none: the normal group). Median EF was 59% (pEF), 40% (rEF), and 59% (normal). Most patients had multivessel coronary artery disease without left main stem stenosis (60%). At 1-year follow-up, some improvements in echo parameters were seen in pEF and rEF. But in the normal group compared to baseline, there were deteriorations in the following: E/é: 7.8-8.9, <i>P</i> < 0.001; NT-proBNP 150-182 ng/L, <i>P</i> = 0.015; and estimated glomerular filtration rate (eGFR) 82.5-78.9 mL/min/1.73 m², <i>P</i> = 0.003. During a median follow-up time of 2.9 years, eight patients (5.8%) died and eight (5.8%) were hospitalized for HF.</p><p><strong>Conclusion: </strong>In patients undergoing elective CABG, signs of LV dysfunction were common and found in 45%. Patients with normal LV function showed signs of worsening systolic and diastolic LV function, eGFR, and NT-pro-BNP at 1-year follow-up.</p><p><strong>Registration: </strong>Clinicaltrials.gov identifier: NCT03671122.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 2","pages":"oeaf014"},"PeriodicalIF":0.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11962374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary haemodynamics by echocardiography over 3 days of acclimatization in lowlanders with chronic obstructive pulmonary disease travelling to 3100 m of high altitude.","authors":"Konstantinos Bitos, Julian Müller, Adilet Omuralieva, Simon R Schneider, Mona Lichtblau, Stéphanie Saxer, Felix C Tanner, Michael Furian, Maamed Mademilov, Talant Sooronbaev, Konrad E Bloch, Silvia Ulrich","doi":"10.1093/ehjopen/oeaf017","DOIUrl":"10.1093/ehjopen/oeaf017","url":null,"abstract":"<p><strong>Aims: </strong>Patients with chronic obstructive pulmonary disease experience an increase in systolic pulmonary artery pressure (sPAP) when exposed to high altitude with an unclear acclimatization. We investigated the effects of acute ascent to 3100 m on pulmonary haemodynamics of patients with chronic obstructive pulmonary disease and their acclimatization during a 3-day stay at high altitude.</p><p><strong>Methods and results: </strong>In this prospective, interventional study, stable, normocapnic patients with chronic obstructive pulmonary disease, with FEV₁ 40-80%predicted and SpO₂ ≥ 92%, residing at low altitude and staying for 3 days/nights at 3100 m without adverse events, were included. Echocardiography was performed at 760 m, directly after arrival at 3100 m (HA1) and the two following days (HA2/HA3). The primary outcome was the change in sPAP at different time points. Additionally, cardiac output (CO), tricuspid annular plane systolic excursion (TAPSE), and other echocardiographic parameters were measured. Thirty-eight patients with chronic obstructive pulmonary disease (37% females), aged (mean ± SD) 55 ± 10years, with FEV₁ 63 ± 12%predicted, were included. After acute ascent to 3100 m vs. 760 m, sPAP increased by 12 mmHg [95% confidence interval (CI): 9-15, <i>P</i> < 0.001], total pulmonary resistance (sPAP/CO) increased by 2 WU (1-3, <i>P</i> = 0.001), and TAPSE/sPAP decreased by -0.6 mm/mmHg (-0.9 to -0.2, <i>P</i> = 0.002). Right atrial pressure and CO were unchanged. At HA3 compared to HA1, sPAP decreased by -4 mmHg (-7 to -1, <i>P</i> = 0.008); no significant changes in further echocardiographic parameters were observed.</p><p><strong>Conclusion: </strong>In stable patients with chronic obstructive pulmonary disease travelling to and staying at 3100 m for 3 days/nights without adverse events, sPAP initially increased, along with an increased pulmonary resistance and a reduced right ventricular-arterial coupling reflected by a lower TAPSE/sPAP. Whereas sPAP steadily decreased during acclimatization, other echocardiographic parameters remained unchanged.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 2","pages":"oeaf017"},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143712325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remnant cholesterol concentrations best explain the cardiovascular benefit of APOC3 genetic inhibition: a drug target Mendelian randomization study.","authors":"Eloi Gagnon, Dipender Gill, Stephen Burgess, Benoit J Arsenault","doi":"10.1093/ehjopen/oeaf018","DOIUrl":"10.1093/ehjopen/oeaf018","url":null,"abstract":"<p><strong>Aims: </strong>Apolipoprotein C-III (APOC3) inhibitors are approved for hypertriglyceridaemia. Genetic evidence suggests that APOC3 inhibition may also prevent coronary artery disease (CAD), but mechanisms remain unclear.</p><p><strong>Methods and results: </strong>To clarify how APOC3 inhibition could prevent CAD, we performed two-step cis-Mendelian randomization using genetic variants in the <i>APOC3</i> gene region associated with plasma levels of APOC3. For comparison, we investigated proprotein convertase subtilisin/kexin type 9 (PCSK9). Potential mediators included apolipoprotein B, triglycerides, LDL-cholesterol, and remnant cholesterol measured by nuclear magnetic resonance spectroscopy in mostly fasting samples from Karjalainen et al., and in non-fasting samples from the UK Biobank. CAD data were from CARDIoGRAMplusC4D. APOC3 associations with apolipoprotein B and remnant cholesterol levels were two-fold larger in the study by Karjalainen et al. (55% fasted individuals) when compared with the UK Biobank study (non-fasted individuals). Genetically predicted lower APOC3 and PCSK9 levels were similarly associated with reduced CAD risk (OR = 0.83, 95% CI = 0.75-0.92, <i>P</i> = 4.6e-04 and 0.76, 95% CI = 0.73-0.80, <i>P</i> = 1.6e-31, respectively). In the two-step cis-Mendelian randomization analysis, the association between genetically predicted APOC3 and CAD was attenuated to null when adjusting for apolipoprotein B, triglycerides, or remnant cholesterol. Multivariable Mendelian randomization using genome-wide variants showed that remnant cholesterol, not triglycerides, was conditionally associated with CAD risk.</p><p><strong>Conclusion: </strong>Remnant cholesterol best explains the mechanism through which APOC3 inhibition could prevent CAD. APOC3 inhibition may influence fasting remnant cholesterol to a greater extent than non-fasting remnant cholesterol. People with high levels of remnant cholesterol could benefit from APOC3 inhibition.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 2","pages":"oeaf018"},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intervention, improved prevention, imaging, inflammation, and innovation: the five I's cardiovascular highlights in <i>EHJ Open</i> 2024.","authors":"Magnus Bäck, Maciej Banach, Frieder Braunschweig, Salvatore De Rosa, Frank A Flachskampf, Thomas Kahan, Daniel F J Ketelhuth, Patrizio Lancellotti, Susanna C Larsson, Linda Mellbin, Gianluigi Savarese, Annette Schophuus Jensen, Karolina Szummer, Denis Wahl","doi":"10.1093/ehjopen/oeaf015","DOIUrl":"10.1093/ehjopen/oeaf015","url":null,"abstract":"","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 1","pages":"oeaf015"},"PeriodicalIF":0.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11878772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143560373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2024 European Society of Cardiology guidelines for chronic coronary syndromes: good news for angina and non-obstructive coronary artery (ANOCA)/ischaemia and non-obstructive coronary artery (INOCA) patients?","authors":"Carolyn M Webb, Maria George, Peter Collins","doi":"10.1093/ehjopen/oeaf016","DOIUrl":"10.1093/ehjopen/oeaf016","url":null,"abstract":"","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 2","pages":"oeaf016"},"PeriodicalIF":0.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11904780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143627153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"15-Year trends, predictors, and outcomes of heart failure hospitalization complicating first acute myocardial infarction in the modern percutaneous coronary intervention era.","authors":"Muhammad Rashid, Dmitry Abramov, Muhammad Usman Naseer, Harriette G C Van Spall, Fozia Z Ahmed, Claire Lawson, Mohamed Dafaalla, Evangelos Kontopantelis, Mohamed O Mohamed, Mark C Petrie, Mamas A Mamas","doi":"10.1093/ehjopen/oeaf013","DOIUrl":"10.1093/ehjopen/oeaf013","url":null,"abstract":"<p><strong>Aims: </strong>Heart failure (HF) following acute myocardial infarction (AMI) is a global health concern, but data on risk factors associated with HF hospitalization post-AMI are limited.</p><p><strong>Methods and results: </strong>We analysed data from the Myocardial Ischaemia National Audit Project, including patients admitted with AMI from 1 January 2006 to 31 March 2019. Data linkage with Hospital Episode Statistics Admitted Patient Care and the Office for National Statistics facilitated a longitudinal analysis. High-risk patients were identified using dapagliflozin in patients without diabetes mellitus with acute myocardial infarction (DAPA-MI) and EMPAgliflozin on Hospitalization for Heart Failure and Mortality in Patients With aCuTe Myocardial Infarction (EMPACT-MI) criteria. We assessed clinical outcomes, adherence to European Society of Cardiology quality indicators, and predictors of HF-related hospitalizations. Out of 1 046 480 AMI patients, 9.1% overall, 17.2% in the DAPA-MI cohort, and 16.6% in the EMPACT-MI cohort experienced HF hospitalization within a year post-AMI. High-risk patients, defined by the presence of five risk factors, had nearly one in four hospitalizations with HF at 1-year follow-up. The predicted adjusted incidence rate for heart failure within 1 year almost doubled from 64.5 cases per 1000 person-years [95% confidence interval (CI): 51.1 to 78.0] in 2005, to 118.2 cases per 1000 person-years in 2019 (95% CI: 115.0 to 121.5). Heart failure hospitalization was associated with a three-fold increase in 1-year mortality (hazard ratio 3.01, 95% CI 2.95-3.13).</p><p><strong>Conclusion: </strong>One in 10 AMI patients experienced HF hospitalization within the first-year post-AMI, with rising trends in high-risk subgroups. These findings highlight the need for targeted post-AMI care strategies to improve outcomes and address the increasing burden of HF in the modern percutaneous coronary intervention era.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 2","pages":"oeaf013"},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}